HBK Sorce Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

HBK Sorce Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,344	Closed	-$285K	–	294
2016 Q3	$285K	Buy	2,344 +52	+2%	+$7.01K	0.06%	221
2016 Q2	$324K	Hold	2,292	–	–	0.07%	195
2016 Q1	$299K	Buy	+2,292	New	+$285K	0.07%	183

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HBK Sorce Advisory's JAZZ Position: Q4 2016 in Review

HBK Sorce Advisory sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 2,344 shares — an estimated $285K sold.

HBK Sorce Advisory first reported a position in JAZZ in Q1 2016 and held it in 3 quarters. The position peaked at $324K in Q2 2016. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

HBK Sorce Advisory reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
HBK Sorce Advisory sold 2,344 Jazz Pharmaceuticals shares in Q4 2016, an estimated $285K.
HBK Sorce Advisory first reported a position in Jazz Pharmaceuticals in Q1 2016 and held it in 3 quarters.
HBK Sorce Advisory's Jazz Pharmaceuticals position peaked at $324K in Q2 2016.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on HBK Sorce Advisory's 13F filing for Q4 2016, filed 14 Feb 2017.